Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets

Lee, V. M.-Y., Brunden, K. R., Hutton, M., Trojanowski, J. Q.·2011·Cold Spring Harbor Perspectives in Medicine
DOI 10.1101/cshperspect.a006437

Cited by (124)

Items 101–124 of 124

  1. Is tau pathology a relevant factor in neuronal damage induced by alcohol and other drugs?
    Margrethe A. Olesen, Andrés Ancía, Rodrigo A. Quintanilla · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  2. Identification of immunogenic cell death-related genes involved in Alzheimer’s disease
    Rui Wang, Yaming Du, Wei Shao, Junli Wang, Xin Liu, Xinzi Xu, Guohua Chen, Yixuan Sun · 2024 · Scientific Reports
  3. Design, synthesis, and biological evaluation of β-secretase inhibitors: An integrated study of molecular docking, dynamics, pharmacokinetics, quantum chemistry, and in-vitro analysis for Alzheimer's disease
    Yamini Patel, Pratibha Sharma, Ashok Kumar, Hamendra Singh Parmar, Gajendra Kumar Inwati · 2025 · Bioorganic Chemistry
  4. Primary or secondary prevention for AD: who cares?
    Giovanni Battista Frisoni, John Q. Trojanowski · 2012 · The Lancet Neurology
  5. Progressive Supranuclear Palsy
    Huw R. Morris · 2017 · Neurodegeneration
  6. ROLE OF ANXA2, HSP90AA1 AND PTK2B IN SYNAPTIC HOMEOSTASIS THROUGH MICROGLIAL CELLS IN THE HUMAN ENTORHINAL CORTEX IN ALZHEIMER’S DISEASE.
    Veronica Astillero‐Lopez, Sandra Villar‐Conde, Melania González-Rodríguez, Alicia Flores‐Cuadrado, Isabel Úbeda‐Bañón, Daniel Saiz‐Sánchez, Alino Martı́nez-Marcos · 2023 · IBRO Neuroscience Reports
  7. Prévenir la progression de la pathologie Tau par immunothérapie passive
    Laurence Ozmen, Ludovic Collin · 2015 · médecine/sciences
  8. Frontiers in Clinical Drug Research - Alzheimer Disorders
    Atta-ur-rahman, Chrystelle Mavoungou, K. S. Zimmerman, John Wright, J. Harding, R. Cavallaro, A. Fuso, Y. Yoshiyama, Zaciragic Asija, A. Clifford et al. · 2015 · BENTHAM SCIENCE PUBLISHERS eBooks
  9. Phosphorylation of a Cleaved Tau Proteoform at a Single Residue Inhibits Binding to the E3 Ubiquitin Ligase, CHIP
    Cory M. Nadel, Kristin Wucherer, Abby Oehler, Aye C. Thwin, Koli Basu, Matthew D. Callahan, Daniel R. Southworth, Daniel A. Mordes, Charles S. Craik, Jason E. Gestwicki · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  10. Molecular Imaging in Alzheimer Clinical Trials
    Mark E. Schmidt, Dawn C. Matthews, Steven G. Staelens · 2016 · Elsevier eBooks
  11. The influence of lysozyme and oligothiophenes on amyloid-β toxicity in models of Alzheimer’s disease
    Linnea Sandin · 2016
  12. Voxel-Wise Image Analysis for White Matter Hyperintensity Segmentation
    Jesse Knight · 2018
  13. Flortaucipir imaging of MAPT
    Corey T. McMillan, Edward D. Huey · 2018 · Neurology
  14. The relation between human biomarkers and oxidative stress in Alzheimer’s disease, novel in vivo experimental modelling possibilities
    Zita Galik-Olah · 2018
  15. Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer
    Luigi Cinquanta, Ignazio Brusca · 2019 · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine
  16. Role of fluid biomarkers in the early diagnosis of Alzheimer’s disease
    Giau Van Vo, Minh Nam Nguyen, Vo Van Toi · 2021 · Science & Technology Development Journal - Health Sciences
  17. Exploring the Potential Interaction between the Functional Prion Protein CPEB3 and the Amyloidogenic Pathogenic Protein Tau
    Ann Teres Babu, Arshad Abdul Vahid, Dhanya S. Reselammal, Safwa T. Kizhakkeduth, Faina Pinhero, Vinesh Vijayan · 2025 · The Journal of Physical Chemistry B
  18. Detection of the Alzheimer's disease soluble amyloid precursor protein and modulation of its proteolytic processing
    Taverna, Mara · 2014 · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)
  19. Therapeutic targeting of CDC-like kinase 1 by bioactive polyphenols for Alzheimer's disease intervention
    Sumaiya Khan, Arunabh Choudhury, Mohammad Shahid, Abdulwahab Abuderman, Md. Imtaiyaz Hassan, Asimul Islam · 2025 · Journal of Molecular Liquids
  20. Les nanotubes comme nouvelle voie de transfert et de propagation de la protéine Tau pathologique
    Meryem Tardivel · 2017 · theses.fr (ABES)
  21. Design, synthesis and characterization of protein-protein interaction disruptors related to early amyloidogenic phenomena in Alzheimer's disease
    Johanna Giovannini · 2021 · theses.fr (ABES)
  22. Mechanism of Paeonolide in Improving Alzheimer’s Disease Based on Network Pharmacology
    享尧 曹 · 2026 · Advances in Clinical Medicine
  23. BindingDB Entry 50048229: MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation.
    BindingDB · 2018 · UC San Diego
  24. BindingDB Entry 50010235: Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties.
    BindingDB · 2021 · UC San Diego